DF/HCC Lung Cancer Program Symposium

Address to event

The Joseph B. Martin Conference Center at Harvard Medical School
77 Avenue Louis Pasteur, Boston MA

The 2016 Symposium will be the 10th primary annual activity organized by the DF/HCC Lung Cancer Program. It is a full-day program that brings together investigators from different scientific disciplines from the seven Harvard Medical School affiliated institutions and leading cancer centers, to share the latest advances in lung cancer and promote and cement collaborations between clinicians and basic scientists.

Agenda:

8:00 - 8:30 AM Continental Breakfast

8:30 - 8:40 AM Introduction

Bruce E. Johnson, MD, Director, Dana-Farber/Harvard Cancer Center Lung Cancer Program, Chief Clinical Research Officer, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School

8:40 - 9:20 AM Genetic Susceptibility to Lung Cancer

Christopher I. Amos, PhD, Associate Cancer Center Director for Population Sciences; Head, Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College

9:20 - 9:30 AM Question & Answer Session

9:30 - 9:50 AM Abstract speaker: TBA

9:50 - 10:10 AM Abstract speaker: TBA

10:10 - 10:20 AM Break: move to 2nd floor lounge

10:20 – 11:20 AM Poster Session (2nd floor lounge)

11:20 - 11:30 AM Break: move back to rotunda

11:30 - 12:10 AM Small Cell Cancer

Charles Rudin, MD, PhD , Chief, Thoracic Oncology Service; Co-Director, Druckenmiller Center for Lung Cancer Research; Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center

12:10 – 12:20 PM Question & Answer Session

12:20 - 1:20 PM Lunch

1:20 - 1:40 PM Abstract speaker: TBA

1:40 – 2:00 PM Abstract speaker: TBA

2:00 – 2:10 pm Break

2:10 – 2:50 PM Ras and Other "Undruggable" Targets

Gregory L. Verdine, PhD, Director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology, DFCI; Erving Professor of Chemistry, Department of Stem Cell and Regenerative Biology, Harvard University; Co-Founder and Chief Executive Officer, Warp Drive Bio

2:50 - 3:00 PM Question & Answer Session

3:00 - 3:40 PM Targeting RAS or Acquired Resistance (tba)

Jeffrey Engelman, MD, PhD, Director, Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center; Associate Professor of Medicine, Harvard Medical School

3:40 – 3:50 PM Question & Answer Session

Pre-registration is required. To register, please contact Juliette Cormier at jlcormier@partners.org